Office of Technology Transfer – University of Michigan

Applications of novel ErbB2 selective peptides

Technology #6579

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Bishnu P. Joshi
Managed By
Tiefei Dong
Senior Licensing Specialist, Life Sciences 734-763-5332
Patent Protection
US Patent Pending

The membrane receptor ErbB2 (also known as HER2/neu) is a member of the epidermal growth factor receptor (EGFR) family. ErbB2 is amplified and overexpressed in many epithelial-derived malignancies including breast, ovarian, and lung cancers. Agents capable of selectively targeting ErbB2 can be used for diagnostics, prognostic indications, imaging and therapeutic applications.

Novel anti-ErbB2 peptides

The inventors have used an in silico approach to identify peptides that bind selectively to ErbB2. These peptides can be used for early non-invasive detection of ErbB2 positive cancer and provide a means to monitor disease progression without the need for a biopsy. Anti-ErbB2 peptides can also be developed to mediate drug delivery specifically to the ErbB2 expressing cancer cells.


  • Early detection of ErbB2 in many types of solid tumors
  • Non-invasive diagnostic approach to identify and monitor ErbB2 positive cancer
  • Therapeutic coupling of peptide with a drug for targeted delivery


  • Peptides have rapid binding kinetics, low toxicity, high target affinity, and are inexpensive to synthesize
  • Peptides can achieve deep tissue penetration with minimal immunogenicity compared to antibodies